Accelerated Cure Project Fall Newsletter Available- September 15, 2008 The latest issue of the Accelerated Cure Project print newsletter is available for download as a PDF. Feature article is on Vitamin D and MS.
Accelerated Cure Project Presents At The 2008 Rare Neuroimmunologic Disorders Symposium- September 15, 2008 The Transverse Myelitis Association & Johns Hopkins ProjectRESTORE sponsored 2008 Rare Neuroimmunologic Disorders Symposium was held in Seattle, WA from July 16th to July 19th. There were many interesting talks, which you can see here, in particular, you can see the talk given about the Accelerated Cure Project Repository here.
Fewer cortical lesions may explain benign MS- September 3, 2008 Here's more evidence that loss of gray matter is a significant factor in MS disability: the reason why some people have a benign course of MS may be because they have fewer lesions in their cerebral cortex. This finding comes from an Italian MRI study which compared 48 people with benign MS to 96 with early relapsing-remitting MS. The benign group had EDSS of 3.0 or less and disease duration of 15 years or more; the early RRMS group also had EDSS of 3.0 or less but a disease duration of 5...
New Zealand Prevalence Study- September 3, 2008 A small country is the first to do a whole country prevalence study of MS. While the numbers varied by region, we see that magic "1 in a 1,000" approximate number popping up yet again. While it seems that MS is so much more prevalent, every study that actually goes and counts MS patients ends up being in that vicinity. Kudos to NZ for actually going and doing this. Wouldn't it be nice if the US, or even one state would do this
Tysabri Label Update- September 3, 2008 Here's some more info on the FDA response to the two new cases of PML with Tysabri. Not sure what this does beyond all the warnings you get when enrolling in the TOUCH program, but hey, somebody needed to do something I guess. A PDF of the new prescribing info is here. On the flip side, here's a study modeling the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis that concludes that a more than sevenfold increase in actual risk of progressive...